-
1.
公开(公告)号:US5861266A
公开(公告)日:1999-01-19
申请号:US203189
申请日:1994-02-28
申请人: Axel Ullrich , Reiner Lammers , Alexei Igorevich Kharitonenkov , Jan M. Sap , Joseph Schlessinger
发明人: Axel Ullrich , Reiner Lammers , Alexei Igorevich Kharitonenkov , Jan M. Sap , Joseph Schlessinger
IPC分类号: A61K38/00 , A61K48/00 , C07C237/16 , C07K14/72 , C07K16/40 , C12N9/16 , G01N33/573 , G01N33/74 , C12Q1/42 , A61K35/78 , A61K39/395 , C12N9/99
CPC分类号: A61K31/7088 , C07C237/16 , C07K14/72 , C07K16/40 , C12N9/16 , G01N33/573 , G01N33/74 , A61K38/00 , A61K48/00 , Y10S514/866
摘要: The present invention relates to novel modalities of treatment of diabetes, and other diseases caused by dysfunctional signal transduction by insulin receptor type tyrosine kinases (IR-PTK). Applicants discovered that IR-PTK activity may be modified by modulating the activity of a tyrosine phosphatase, and IR-PTK signal transduction may be triggered even in the absence of ligand. Methods for identifying compounds that, by modulating RPTP.alpha. or RPTP.epsilon. activity, elicit or modulate insulin receptor signal transduction are also described.
摘要翻译: 本发明涉及由胰岛素受体型酪氨酸激酶(IR-PTK)的功能障碍信号转导引起的糖尿病治疗的新型方式。 申请人发现,通过调节酪氨酸磷酸酶的活性可以修饰IR-PTK活性,即使不存在配体也可能引发IR-PTK信号转导。 还描述了通过调节RPTPα或RPTPε活性,引发或调节胰岛素受体信号转导来鉴定化合物的方法。